"Rare Diseases in Young Adults" is the title of the latest publication sponsored by Lusofarmaco, member company of the Menarini Group, recently distributed to Italian physicians.

The Menarini Group has always given particular attention to rare diseases, dedicating research projects to ‘orphan’ diseases such as: the study for a vaccine against cancer of the ovaries, a project on a third generation anti-cancer drug against microcitoma of the lung, and the development of a new biotechnological drug for the treatment of a rare and serious disease afflicting children in paediatric age.

" We will continue to focus on rare diseases by providing updated scientific texts, and this is a concrete and substantial commitment undertaken by the company in order to support both the GP and his patients. Indeed this latest publication includes, for each pathology cited, the information necessary to support the physician, ranging from photographic material to patient associations and exemption codes …" commented Dr. Giulio Vignaroli, General Manager of Lusofarmaco.